Apogee Therapeutics, Inc. ( (APGE)) has released its Q3 earnings. Here is a breakdown of the information Apogee Therapeutics, Inc. presented to its investors. Apogee Therapeutics, Inc. is a ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2 Part ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on October 28. Tyler Van Buren has ...

Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

After hours: November 12 at 6:17 PM EST Loading Chart for APGE ...

This page features the latest news about the Apogee Therapeutics share. Stifel maintains Buy on Apogee Therapeutics with $95 target On Tuesday, Stifel reiterated its Buy rating on Apogee (NASDAQ:APOG) ...